SmallCapsDaily: G Medical Innovations is an Ideal Blend of Growth and Profitability

New York, New York–(Newsfile Corp. – September 8, 2021) – G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) (the “Company”), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, was recently the focus of an article by leading financial news website and publisher, SmallCapsDaily. The article is a thorough synopsis of G Medical’s positioning within the healthcare industry, more specifically, the mobile health or “mHealth” sector. Through its development of the Prizma, a plug-and-play medical device that communicates with a user’s smartphone, and allows its users to measure ECG, Heart rate, SpO2, body temperature and stress (HRV) at clinical grade reporting standards and accuracy, the company has created its own eco-system (Remote Vital Signs Monitoring System) within the health care system. G Medical has also developed the VSMS Extended Holter Patch System, a biosensor lasting 14 days, which is connected to a user’s chest to record multi-channel (6 leads) ECG data, which can be transmitted in near real time to G Medical’s clinical center and reported to doctors for review. Given G Medical’s novel, proprietary technology and innovative suite of products, the company’s growth and profitability outlook is positive.

For more detailed information, please click here for the full article at the SmallCapsDaily website.

Key Takeaways

• G Medical’s growth strategy focuses on business-to-business and business-to-consumer sales with their customers including hospitals, senior care facilities and the patients themselves.
• G Medical has seen their revenue grow from $109,000 in 2017 to $5.53 million in 2019, a CAGR of 612%. Revenue in 2020 was reduced to $4.9 million due to the economic impact of COVID-19 but despite this, the company was able to improve their operating margin from a loss of 5.5% in 2017 to a profit of 21% in 2020.
• On May 14, 2020, G Medical received emergency authorization by the FDA for the use of their VSMS ECG Patch to be used in a hospital setting, allowing healthcare professionals to remotely monitor a patient’s heart who are also undergoing treatment for COVID-19 with prescription drugs that, in some cases can cause life threatening arrhythmias.

About G Medical Innovations Holdings Ltd.
G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. For more information, please visit https://gmedinnovations.com/.

Forward-Looking Statements
SmallCapsDaily profiles are not a solicitation or recommendation to buy, sell or hold securities. SmallCapsDaily is a paid advertiser and is not offering securities for sale. Neither SmallCapsDaily nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by SmallCapsDaily its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. Small Caps Daily does not recommend that the securities profiled should be purchased, sold or held and is not liable for any investment decisions by its readers or subscribers. Information presented by Small Caps Daily may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance, are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as “expects,” “will,” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating that certain actions “may,” “could,” or “might” occur.

Contact:

SmallCapsDaily
info@smallcapsdaily.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/95853.